Market Overview

Merck Presents Early-Stage Interim Data for MK-3475 Study for Treatment of Advanced Melanoma


Merck (NYSE: MRK) announced Sunday the presentation of early interim results from a
single-arm, open-label Phase IB study that has so far enrolled 132
patients with advanced (inoperable and metastatic) melanoma who have
received MK-3475, Merck's investigational immune-modulating
therapy. Omid Hamid, M.D., Director of the Melanoma Center at the
Angeles Clinic and Research Institute, Los Angeles, presented the data
during a late-breaking clinical trials session at the Society for
Melanoma Research of the 9th International Congress of the Society for
Melanoma Research (SMR) in Hollywood, Calif.

"A key element of Merck's oncology strategy is to identify therapeutic
candidates with the potential to make a meaningful difference

See full press release

Posted-In: News Guidance Management Global


Related Articles (MRK)

View Comments and Join the Discussion!